Table 5

Prevalence of comorbidity codes in the anticoagulant treated and untreated populations of those in whom anticoagulation is recommended by CHADS₂ ≥2, (n = 34 041)

	Prevalence of the comorbidity code in the population in which anticoagulation is recommended according to CHADS₂ ≥2 (%)

	Overall, n = 34 041	Treated group, n = 18 042	Untreated group, n = 15 999	P-value
Haemorrhagic stroke or intracranial haemorrhage	2.0	1.2	3.0	<0.001

Post-traumatic intracranial haemorrhage	0.2	0.1	0.4	<0.001

Allergy to warfarin/other anticoagulants	1.8	2.4	1.2	<0.001

History of GI tract bleeding	5.4	4.3	6.6	<0.001

Uncontrolled blood pressure^a	80.0	79.2	80.9	<0.001

Bleeding tendency	2.5	2.7	2.3	0.013

History of other bleeding	13.6	15.2	11.8	<0.001

History of bruising	2.2	2.2	2.2	0.80

Falls	4.7	3.2	6.3	<0.001

Other significant injury	37.2	34.7	39.9	<0.001

Peptic ulceration and other upper GIT disorders	30.9	28.9	33.1	<0.001

GIT malignancy — at any time	2.8	2.3	3.4	<0.001

GIT malignancy — 1 October 2005 or later	1.5	1.2	1.8	<0.001

Other malignancy — at any time	17.0	16.2	17.9	<0.001

Other malignancy — 1 October 2005 or later	10.9	10.5	11.4	0.006

Liver dysfunction/disease	5.2	5.3	5.1	0.53

Chronic kidney disease	2.0	2.0	2.1	0.81

Anaemia	13.7	11.9	15.9	<0.001

Alcohol abuse^b	11.0	11.8	10.1	<0.001

Epilepsy	2.1	1.9	2.2	0.033

Terminal illness	0.2	0.2	0.3	0.042

Dementia	1.1	0.6	1.7	<0.001

Drugs used for dyspepsia	40.7	34.9	47.3	<0.001

Anti-inflammatory drugs	27.8	23.6	32.5	<0.001

GIT = gastrointestinal tract.
↵a Specific definition available from the authors.
↵b Codes available from the authors.